Fexofenadine in horses: Pharmacokinetics, pharmacodynamics and effect of ivermectin pretreatment

Journal of Veterinary Pharmacology and Therapeutics

Volumn 29, Issue 2, 2006, Pages 129-135

  Olsen L ^a   Ingvast Larsson, C ^a   Larsson, P ^a   Brostrom H ^a   Bondesson, U ^b,c   Sundqvist, M ^d   Tjalve H ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

^d Östra Greda Research Group   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FEXOFENADINE; GLYCOPROTEIN P; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IVERMECTIN; NOROMECTIN; ORGANIC ANION TRANSPORTER 2;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HORSE; INTESTINE ABSORPTION; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URTICARIA;

ANIMALS; ANTIPARASITIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HISTAMINE H1 ANTAGONISTS; HORSES; IVERMECTIN; TERFENADINE;

EQUIDAE; EQUUS CABALLUS;

EID: 33644686801     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/j.1365-2885.2006.00724.x     Document Type: Article

References (36)

1. Adams R.H. 1995 Histamine, serotonin, and their antagonists In Veterinary Pharmacology and Therapeutics 7th edn, Sec. 4, Ch. 18 Ed. Richard Adams H pp 401 411 Iowa State University Press Ames, IA
2. Baggot J.D. 1992 Bioavailability and bioequivalence of veterinary drug dosage forms, with particular reference to horses: an overview Journal of Veterinary Pharmacology and Therapeutics 15 160 173
3. Benet L.Z. Cummins C.L. 2001 The drug efflux-metabolism alliance: biochemical aspects Advanced Drug Delivery Reviews 50 Suppl. 1 S3 S11
4. Benet L.Z. Izumi T. Zhang Y. Silverman J.A. Wacher V.J. 1999 Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery Journal of Controlled Release 62 25 31
5. Campbell W.C. 1985 Ivermectin: an update Parasitology Today 1 10 16
6. Cvetkovic M. Leake B. Fromm M.F. Wilkinson G.R. Kim R.B. 1999 OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine Drug Metabolism and Disposition 27 866 871
7. Didier A. Loor F. 1996 The abamectin derivate ivermectin is a potent P-glycoprotein inhibitor Anti-Cancer Drugs 7 745 751
8. Dresser G.K. Bailey D.G. Leake B.F. Scwartz U.I. Dawson P.A. Freeman D.J. Kim R.B. 2002 Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral bioavailability of fexofenadine Clinical Pharmacology & Therapeutics 71 11 20
9. Dresser G.K. Kim R.B. Bailey D.G. 2005 Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides Clinical Pharmacology & Therapeutics 77 170 177
10. Foster A.P. McKelvie J. Cunningham F.M. 1998 Inhibition of antigen-induced cutaneous responses of ponies with insect hypersensibility by histamine-1 receptor antagonist chlorphentamine The Veterinary Record 143 189 193
11. Hamman M.A. Bruce M.A. Haehner-Daniels B.D. Hall S.D. 2001 The effect of rifampin administration on the disposition of fexofenadine Clinical Pharmacology & Therapeutics 69 114 121
12. Kamath A.V. Yao M. Zhang Y. Chong S. 2005 Effect of fruit juices on the oral bioavailability of fexofenadine in rats Journal of Pharmaceutical Sciences 94 233 239
13. Kararli T.T. 1995 Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals Biopharmceutics and Drug Disposition 16 351 380
14. Kim R.B. Leake B.F. Choo E.F. et al. 2001 Identification of functionally variant of MDR1 alleles among European Americans and African Americans Clinical Pharmacology & Therapeutics 70 189 199
15. Krishna R. Krishnaswami S. Kittner B. Sankoh A.J. Jensen B.K. 2004 The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride Biopharmaceutics & Drug Disposition 25 373 387
16. Laffont C.M. Toutain P.L. Alvinerie M. Bousquet-Melou A. 2002 Intestinal secretion is a major route for parent ivermectin elimination in the rat Drug Metabolism and Disposition 30 626 630
17. Lippert C. Ling J. Brown P. Burmaster S. Eller M. Cheng L. Thompson R. Weir S. 1995 Mass balance and pharmacokinetics of MLD 16455A in healthy male volunteers Pharmaceutical Research 12 S390
18. Liu H. Farley J.M. 2005 Effects of first and second generation antihistamines on muscarinic induced mucus gland cell ion transport BMC Pharmacology 5 8
19. Morrow A. Quinn P.J. Baker K.P. 1986 Dermal reactivity to histamine, serotonin and bradykinin in relation to allergic skin reactions of the horse Journal of Veterinary Pharmacology and Therapeutics 9 40 48
20. Nozawa T. Imai K. Nezu J. Tsuji A. Tamai I. 2004 Functional characterisation of pH sensitive organic anion transporting polypeptide OATP-B in human The Journal of Pharmacology and Experimental Therapeutics 308 438 445
21. Orzechowski R.F. Currie D.S. Valancius C.A. 2005 Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models European Journal of Pharmacology 506 257 264
22. Perloff M.D. von Moltke L.L. Greenblatt D.J. 2002 Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir Journal of Clinical Pharmacology 42 1269 1274
23. Putnam W.S. Ramanathan S. Pan L. Takahashi L.H. Benet L.Z. 2002 Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells Journal of Pharmaceutical Sciences 91 2622 2635
24. Rosenkrantz W.S. 1995 Systemic/topical therapy The Veterinary Clinics of North America Equine Practice 11 127 146
25. Russell T. Stoltz M. Weir S. 1998 Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers Clinical Pharmacology & Therapeutics 64 612 621
26. Schinkel A.H. Smit J.J. van Tellingen O. Beijnen J.H. Wagenaar E. van Deemter L. Mol C.A. van der Valk M.A. Robanus-Maandag E.C. Riele H.P. 1994 Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs Cell 77 491 502
27. Simpson K. Jarvis B. 2000 Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria Drugs 59 301 321
28. Skálová L. Szotakova B. Machala M. Neca J. Soucek P. Havlasova J. Wsol V. Kridova L. Kvasnickova E. Lamka J. 2001 Effect of ivermectin on activities of cytochrome P450 isoenzymes in mouflon (Ovis musimon) and fallow deer (Dama dama) Chemico-Biological Interactions 137 155 167
29. Tahara H. Kusuhara H. Fuse E. Sugiyama Y. 2005 P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion Drug Metabolism and Disposition 33 963 968
30. Tannergren C. Petri N. Knutson L. Hedeland M. Bondesson U. Lennernäs H. 2003a Multiple transport mechanisms involved in the intestinal absorbtion and first-pass extraction of fexofenadine Clinical Pharmacology & Therapeutics 74 423 436
31. Tannergren C. Knutson T. Knutson L. Lennernäs H. 2003b The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique British Journal of Clinical Pharmacology 55 182 190
32. Törneke K. Ingvast-Larsson C. Pettersson K. Bergvall K. Hedeland M. Bondesson U. Broström H. 2003 Pharmacokinetics and pharmacodynamics of clemastine in healthy horses Journal of Veterinary Pharmacology and Therapeutics 26 151 157
33. Toutain P.L. Lees P. 2004 Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine Journal of Veterinary Pharmacology and Therapeutics 27 467 477
34. Toutain P.L. Autefage A. Legrand C. Alvinerie M. 1994 Plasma concentration and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling Journal of Veterinary Pharmacology and Therapeutics 17 459 469
35. Tydén E. Olsén L. Tallkvist J. Larsson P. Tjälve H. 2004 CYP3A in horse intestines Toxicology and Applied Pharmacology 201 112 119
36. Yasui-Furukori N. Uno T. Sugawara K. Tateishi T. 2005 Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics Clinical Pharmacology & Therapeutics 77 17 23